This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
The smoking-cessation drug, reformulated for nasal delivery, could be launched for dry eye, Oyster Point hopes.
New consensus forecasts stretching out to 2026 see Roche easily retaining its crown as the world’s biggest drugmaker, while Bristol-Myers Squibb climbs the rankings.
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.